1 Modelling the potential use of pre-exposure prophylaxis to reduce nosocomial

2 SARS-CoV-2 transmission

- 3
- 4 Lauren Stewart¹, Stephanie Evans^{2,3}, Teresa Brevini⁴, Fotios Sampaziotis^{4,5,6},
- 5 Christopher J. R. Illingworth¹
- 6
- ⁷ ¹MRC University of Glasgow Centre for Virus Research, Glasgow, UK
- ²Fungal, HCAI, AMU & Sepsis Division, UK Health Security Agency, London, AMR,
- 9 UK
- ³Statistics, Modelling and Economics, UK Health Security Agency, London, UK
- ⁴Wellcome–MRC Cambridge Stem Cell Institute, Cambridge, UK
- 12 ⁵Cambridge Liver Unit, Cambridge University Hospitals NHS Foundation Trust,
- 13 Cambridge, UK
- ⁶Department of Medicine, University of Cambridge, Cambridge, UK
- 15

16 Abstract

- 17 The nosocomial transmission of respiratory pathogens is an ongoing healthcare
- 18 challenge, with consequences for the health of vulnerable individuals. Outbreaks in
- 19 hospitals can require the closure of bays or entire wards, reducing hospital capacity
- 20 and having a financial impact upon healthcare providers. Here we evaluate a novel
- 21 strategy of pre-exposure prophylaxis as a means to reduce the nosocomial
- transmission of SARS-CoV-2. We model the effect of ursodeoxycholic acid (UDCA)
- 23 upon levels of ACE2 expression, SARS-CoV-2 viral entry, and ultimately the
- 24 probability of an infection. We then implement this model within simulations
- 25 describing the spread of SARS-CoV-2 infections within a hospital context, simulating NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 an intervention in which UDCA is given to patients on a ward for 10 days following the detection of a case of SARS-CoV-2 on that ward. Under default model 27 parameters we infer a potential 16.5% reduction (95% C. I. 14% - 20%) in the 28 29 nosocomial transmission of SARS-CoV-2 to patients, with increased importation of cases into the hospital increasing the effectiveness of the intervention. Our study 30 provides preliminary evidence of the value of pre-exposure prophylaxis with UDCA 31 32 as a strategy to reduce nosocomial SARS-CoV-2 transmission. 33 34 Introduction

The SARS-CoV-2 virus has had a major impact upon human health^{1,2}. As such, a key priority has been the identification of public health interventions which either prevent or reduce the impact of infection.

39

35

Vaccines have been shown to reduce the chances of infection leading to 40 hospitalisation or death³, albeit that the immunity gained from vaccination wanes 41 over time⁴, while virus evolution creates a need to continually re-evaluate vaccine 42 effectiveness⁵. Other lines of defence against SARS-CoV-2 include antiviral drugs, 43 such as pavloxid⁶, remdesivir⁷ and molnupiravir⁸. The US Food and Drug 44 45 Administration has issued an emergency use authorisation for a monoclonal antibody therapy for pre-exposure prophylaxis⁹. These interventions have their own 46 limitations, with for example a five-day course of molnupiravir being associated with 47 a lower SARS-CoV-2 viral load five days after treatment, but a higher viral load after 48 14 davs¹⁰. Non-pharmaceutical interventions, such as handwashing, masking, and 49 social distancing, have helped to prevent infection¹¹. 50

51

Hospitals and care homes have been the focus of particular attention in the 52 monitoring and prevention of SARS-CoV-2 transmission. Even as the consequences 53 of COVID have attenuated for the general population¹², the concentration of 54 potentially vulnerable individuals in these environments creates an enhanced need 55 for action. One study early in the pandemic estimated that close to 15% of SARS-56 CoV-2 cases in hospital were the result of hospital-acquired infection¹³. Accordingly, 57 studies have evaluated the use of mask-wearing by health care workers and patients 58 in hospitals^{14,15}. The installation of air cleaning units on a hospital ward was shown 59 to reduce the concentration of airborne particulates of a size commensurate with 60 airborne viral transmission¹⁶. Air cleaning has been associated with a 22% reduction 61 62 in nosocomial transmission (95% CI 47% to -14%)¹⁷.

63

A mathematical study identified pre-exposure prophylaxis (PrEP) as being potentially 64 65 the most effective complement to vaccination in preventing SARS-CoV-2 infection¹⁸. Mathematical modelling provides a valuable insight into potential therapeutic 66 approaches in advance of committing financial and clinical resources to a real-world 67 trial. However, PrEP approaches to combatting SARS-CoV-2 are not simply 68 theoretical constructs. A Mendelian randomisation study of potentially druggable 69 70 proteins identified the genes ACE2 and IFNAR2 as priority targets for intervention¹⁹. 71 The former is a cell receptor which critically must be bound by SARS-CoV-2 Spike protein prior to cellular entry²⁰, while the latter participates in the host innate immune 72 response²¹ against the virus. ACE2 expression has been associated with more 73 severe clinical outcomes of SARS-CoV-2 infection²². 74

76 The discovery that the farnesoid X receptor (FXR) regulates ACE2 expression provided a novel approach to controlling SARS-CoV-2 infection²³. Ursodeoxycholic 77 acid (UDCA) is a well-tolerated and off-patent drug which downregulates FXR, 78 79 leading to a reduction in ACE2 expression. A cohort study identified a significant reduction in the odds of developing SARS-CoV-2 infection among patients with 80 cirrhosis who were treated with UDCA²⁴, finding also a reduced risk of disease 81 82 severity among treated individuals. Although another study found no significant reduction in the risk of hospitalisation for COVID among treated individuals²⁵, the 83 basic result has been replicated in independent studies^{26,27}, with high adherence to 84 UDCA treatment²⁸, and an increased dose of UDCA²⁹ being associated with reduced 85 rates of infection. A contrary result was reported in a smaller cohort of patients³⁰. 86

87

88 While clinical studies have compared individuals treated with UDCA to those not 89 receiving the drug, there may exist a broader scope to use the drug in a responsive 90 fashion, for example as pre-exposure prophylaxis given an anticipated period of 91 greater risk of SARS-CoV-2 infection.

92

In this study we use a mathematical model to evaluate the potential for UDCA to 93 94 reduce nosocomial transmission. Our model encompasses the multiple scales on 95 which the drug affects transmission, including the time-dependent effect of UDCA upon ACE2 expression, the relationship between ACE2 expression and SARS-CoV-2 96 viral entry into cells, and the distribution of levels of exposure occurring during a 97 98 potential transmission event. Briefly, our model describes the effect of UDCA in terms of a change in the distribution of effective levels of viral exposure. SARS-CoV-99 2 exposures vary according to a range of individual and environmental factors³¹, 100

101 such as the distance from an infected host. We characterise exposure in units of the number of viruses expected to initiate infection, using published data describing 102 transmission bottlenecks³² and secondary attack rates³³ for SARS-CoV-2 to derive 103 104 an exposure distribution (Figure 1A). Treatment with UDCA reduces ACE2 expression (Figure 1B), and therefore the proportion of viruses to which a person is 105 exposed that initiate infection. This occurs in a time-dependent manner after the 106 107 beginning of treatment, and is represented in our model in terms of a modification to the exposure distribution (Figure 1C). Our model describes a situation in which 108 109 UDCA treatment reduces the probability that an exposure will lead to infection, lowering the odds ratio of infection (Figure 1D). 110 111 112 This mathematical approach enables the *in silico* evaluation of potential strategies 113 for using UDCA to reduce SARS-Cov-2 infection; we here evaluate the potential effect of UDCA being administered to patients on a ward following the detection of a 114 115 case of SARS-CoV-2. Details of the derivation of our basic model are shown in Supplementary Figures S1 to S3. 116 117 Results 118 119 120 Hospital-based transmission 121 We integrated our model of UDCA treatment and SARS-CoV-2 infection within a 122 123 larger model describing nosocomial transmission in a hospital environment. 124 Simulations were run to describe an environment in which UDCA was not used, with

125 the effect of treatment being represented by retrospective changes made to each

126 simulation. Data from an outbreak extracted from one simulation shows how UDCA had the potential to cut short chains of transmission events (Figure 2A). In this case, 127 an infected individual, with ID number 953, was introduced onto a ward, leading to a 128 129 large outbreak involving both patients and healthcare workers. We simulated an intervention in which, upon the detection of a case of SARS-CoV-2 on a ward, all 130 patients on that ward, plus any arriving onto that ward during the intervention, were 131 132 treated for 10 days with UDCA. Changes in individual probabilities of being infected upon the intervention are shown in Figure 2B. Here, the ward onto which patient 953 133 134 was introduced was already marked as an intervention ward, so that patients in 135 contact with patient 953, and those further down the network, were already treated with UDCA. In our simulation this reduced the probability of those patients being 136 137 infected, further reducing the probabilities of individuals further down the 138 transmission chain from being infected. Healthcare workers in the network were not treated, but acquired a lower risk of infection via a reduction in exposure to infected 139 140 patients. Across multiple transmissions within the network the probability of an individual being infected can be greatly reduced; for example the intervention results 141 in the individual 4665 having only a 7.5% chance of being infected. Within this 142 network the numbers of secondary infections were reduced from 7 patients and 8 143 HCWs to a mean of 1.9 patients and 4.6 HCWs (Figure 2C/D). 144

145

Applied to a set of simulated data, describing nosocomial transmission in 60
hospitals over a window of 610 days, our simulated intervention reduced cases of
nosocomial transmission among patients by 16.5% (95% C. I. 14% - 20%) (Figure
3A). As modelled, the intervention reduced nosocomial infection of HCWs by close
to 4% (Figure 3B). These figures are lower than obtained for the example network of

Figure 2, which was an outlier in terms of its large size. Across hospital simulations,
the most common instance of nosocomial transmission involved one person infecting
another, with no further transmission. The mean transmission network involved 3.1
individuals, or equivalently 2.1 cases of nosocomial transmission (Supplementary
Figure 3).

156

157 Our results were sensitive to the parameters of our model. For example, changing the window of intervention following the detection of a case led to changes in the 158 159 reduction of nosocomial transmission among patients, from 16.5% at the default 10-160 day window of intervention to 10.3% for a 6-day window of intervention, or to 22.6% 161 for a 14-day window of intervention (Figure 3C). Changing the length of the 162 intervention window led to proportional changes in the number of ward-days for 163 which the intervention was in place. Where under default parameters, the intervention was in place for a mean of 7440 ward-days, this statistic ranged 164 165 between 5270 ward-days given a 6-day intervention to 9610 ward-days given a 14day intervention (Figure 3D). 166

167

The effect of the intervention was also sensitive to the simulated level of community 168 169 infection, which in our model determines the rate of importation of SARS-CoV-2 170 patients into a hospital. Halving the importation rate compared to the default led to 171 an estimated 11% reduction in nosocomial cases in patients, while doubling the rate of importation relative to default led to an estimated 24% reduction in nosocomial 172 173 cases (Figure 4A, B). Although a higher importation rate led to more cases of SARS-CoV-2 in hospital, and an increased number of cases of nosocomial transmission, 174 175 the distribution of the sizes of transmission networks was not substantially altered

176 (Figure S4). Rather, the difference in outcome arises from an indirect effect of the number of cases: A greater number of cases in hospital meant that more 177 transmission networks occurred on wards that had previously been marked out for 178 179 intervention. UDCA has a time-dependent effect on ACE2 expression levels. In a hospital where SARS-CoV-2 outbreaks are sparse, there are few wards on which the 180 intervention is in place. Given a new outbreak there is a delay arising from the time 181 182 taken to detect a new outbreak, and then the time taken for UDCA treatment to have full effect, before the full impact of the drug is experienced. By contrast, where 183 184 outbreaks are common, the probability of a new outbreak arising on a ward in which 185 the intervention is already in place is increased. In such a case the delay is reduced, 186 with UDCA potentially providing its maximal benefit from the first day of the outbreak. 187 We note that, at the modelled high rate of importation, a situation is reached in which, at peak, nearly all hospital wards are included in the intervention (Figure 4C, 188 D). At this point any new cases of nosocomial transmission occurring in the hospital 189 190 involve already-treated patients, maximising the effect of the intervention.

191

192 Discussion

193

We have here considered the use of a potential candidate for use as pre-exposure prophylaxis against SARS-CoV-2 infection. Our approach combines mathematical models of changes in ACE2 expression, the consequences of those changes for virus entry into cells, and the likely levels of exposure to the virus encountered by individuals; combined these models produce a result consistent with observational studies. Applying our model to simulated data describing a hospital setting, our approach suggests that a proposed intervention using the drug might lead to a

reduction of around 17% in nosocomial transmission to patients. Our work provides
 an indicative and preliminary assessment of the potential for UDCA as to be used for
 pre-exposure prophylaxis to combat nosocomial transmission.

204

Our modelling provides some insight into the potential value of pre-exposure 205 prophylaxis in a real-world setting. Where modelling has suggested the use of pre-206 207 exposure prophylaxis as an effective tool to prevent SARS-CoV-2 infection, the implicit need for action to be taken prior to an exposure limits its value. In modelling 208 209 a hospital outbreak we have chosen a setting in which the potential risk of infection is 210 unusually high, in which cases of infection are being actively monitored, and in which 211 treatment could be administered by competent medical professionals. In this setting, 212 the time-dependent effect of treatment was predicted to have an effect. A proportion 213 of the effectiveness of the intervention is explained by the reduction in transmission 214 events withing outbreaks that occur on an intervention ward but are unrelated to the 215 outbreak which triggered the intervention.

216

In this sense, our work highlights a distinction between preparatory and responsive 217 approaches to reducing infectious disease transmission. Preparatory approaches, 218 219 such as improving ventilation, mask-wearing, and hand hygiene, create an 220 environment in which transmission is intrinsically less likely. Responsive 221 approaches, which are implemented following the detection of an outbreak, are 222 limited by imperfect surveillance, and in the case of UDCA, by transmission events 223 having occurred prior to the intervention taking effect. Our calculated reduction in transmission of 17% compares to a recent study suggesting a 22% reduction in 224 transmission with the use of improved ventilation¹⁷, but may be optimistic. The levels 225

of community importation into the hospital may be lower than reflected in the
assumptions underlying the simulation, such that the effectiveness of the intervention
we model would be reduced.

229

Our model has some implications regarding SARS-CoV-2 transmission, for example 230 that people with higher baseline levels of ACE2 expression are more likely to be 231 232 infected with SARS-CoV-2. Where someone's baseline ACE2 expression level is high, more of the viruses they are exposed to are likely to gain entry into cells and 233 234 initiate infection. Our model also implies that a high baseline ACE2 expression level 235 will reduce the efficacy of UDCA in preventing infection. UDCA reduces the number 236 of viruses entering cells, but to prevent infection this number must be reduced to 237 zero. The reduction to zero is less likely when the initial number, due to high ACE2 expression, is large. Figure S5 describes expected reductions in transmission for 238 high and low baseline levels of ACE2 expression. 239

240

241

Our modelling approach is built upon multiple assumptions. For example, our model 242 of exposure to SARS-Cov-2 was constructed using data describing transmission in a 243 244 domestic, rather than a hospital setting. The simulated hospital environment, while 245 representing the state of the art, also contains multiple simplifications. For example, 246 a healthcare worker who avoided being infected due to the indirect effect of UDCA 247 would retain a risk of being infected at some later date via the local community. Our 248 simulated approach neglected this risk: Once prevented from being infected on one 249 occasion, HCWs stayed uninfected for the remainder of the simulation. As such our 250 result about preventing infection in healthcare workers is open to some uncertainty.

251 Our model assumes that the distribution of ACE2 levels in the hospital population mirror those of the general population. Further, simulations of hospitals simplify 252 elements such as the movement of patients and staff between wards which likely 253 254 impact upon transmission. Differences between hospital environments, such as those of hospital architecture, are not captured by our model. However our simple 255 mathematical model describing the effect of UDCA upon SARS-CoV-2 transmission 256 257 gave a result consistent with that described in a cohort study. Previously, John et al found an adjusted odds ratio for risk of symptomatic COVID infection of 0.54 258 259 (confidence interval 0.39 – 0.73) among individuals with cirrhosis who were treated with UDCA²³. Considering an individual who had been treated for at least 3 days 260 261 prior to exposure to SARS-CoV-2, our model suggested that continuous treatment 262 with UDCA would reduce the incidence of COVID infection by 56%, equivalent to an 263 adjusted odds ratio of 0.44.

264

265 The intervention we propose is described in a simplified fashion. Although long-term therapy with UDCA is well-tolerated³⁴, aspects such as negative drug-drug 266 interactions may prevent the giving of the drug in a universal manner to a cohort of 267 patients. We have here considered the use of UDCA for pre-exposure prophylaxis in 268 269 a situation where full clinical supervision is possible. A realistic intervention might 270 use the drug only in subsets of cases where SARS-CoV-2 infection would have 271 particularly severe consequences, such as in a care home or with more vulnerable 272 patients. The authors do not recommend the use of UDCA in any situation except 273 under the explicit guidance of a gualified physician.

274

275 Methods

277	We built a model to estimate the effect of treatment with UDCA upon SARS-CoV-2
278	transmission. Our model has three parts, the first modelling the effect of UDCA upon
279	ACE2 expression in an individual, the second modelling the effect of changing ACE2
280	expression upon virus entry into cells, and the third modelling the likely distribution of
281	exposure to SARS-CoV-2 viruses, given knowledge of transmission bottlenecks from
282	cases of SARS-CoV-2 infection.
283	
284	Changes in ACE2 expression given treatment with UDCA

285

286 Given data from a set of individuals describing variation in ACE2 levels after

commencing treatment with UDCA²³, we used a time-dependent gamma distribution

to represent the effects of the drug. In this equation x describes ACE2 expression

level. The Mathematica software package was used to identify optimal parameters aand b within this model.

291

$$G(a, b, t, x) = P(ACE2 = x | a, b, t) = \frac{x^{a(t)-1}b(t)^{-a(t)}e^{-x/b(t)}}{\Gamma(a(t))}$$
(1)

292

293

G(a,b,t) was here characterised using data describing three discrete time intervals, for t=0 days, t \in {1, 2} days, and t \geq 3 days. Raw data are shown in Figure S1; the inferred distributions are shown in Figure 1B.

- 297
- 298

299 Modelling of the relationship between ACE2 expression and viral infection

300		
301	Data describing ACE2 expression and SARS-CoV-2 infection levels from different	ent
302	cell types within a lung explant was used for modelling purposes ²³ . Under a mo	odel
303	of receptor association, the relationship between ACE2 receptor availability and	t virus
304	entry are expected to follow the Hill equation ³⁵ . To explore whether, at the	
305	physiological concentrations of ACE2 represented by our data, a linear model v	vould
306	be a reasonable approximation to this, we fitted both linear and sigmoidal curve	es to
307	the data. Where the level of ACE2 expression is given by [ACE2], our models	were
308		
309	Linear model:	
310		
	V = a[ACE2]	(2)
311		
312		
313	Hill equation:	
314		
	$V = \frac{m[ACE2]^a}{c + [ACE2]^a}$	(3)
315		
316	Models were fitted to the data using the NonlinearModelFit routine within the	
317	Mathematica software package, inferring different parameters for the lung and	
318	bronchaeal data; these data were not directly comparable due to different cell	
319	compositions of the different samples. Model fits were compared using the Bay	esian
320	Information Criterion (BIC) ³⁶ . The difference between the BIC values for the material states and the st	odels,

- 321 of 2.81 units in favour of the Hill equation model, was interpreted as positive support
- 322 for this model but not strong support, following Raferty et al³⁷. Data used in this
- modelling, and model fits, are shown in Figure S2.
- 324
- 325 Inference of a distribution of levels of exposure to virus
- 326
- 327 We generated a model of the number of viruses expected to initiate infection during
- 328 SARS-CoV-2 transmission. Given a level of exposure to viruses E, we modelled the
- 329 transmission bottleneck size N_b (i.e. the number of viruses initiating an infection³⁸) as
- being Poisson distributed with parameter E.
- 331

$P(N_b = n E) = \frac{E^n e^{-E}}{n!}$	(4)

- 332
- 333

We assumed that exposure can be described by a Gamma distribution, such that Eobeys the formula

336

$$P(E = x | \alpha, \beta) = \frac{x^{\alpha - 1} \beta^{-\alpha} e^{-x/\beta}}{\Gamma(\alpha)}$$
(5)
337

338

339 Where $\Gamma(\alpha)$ describes the gamma function

$$\Gamma(\alpha) = \int_0^\infty t^{\alpha - 1} e^{-t} dt$$
⁽⁶⁾

341

342

343	We next inferred parameters α and β for this model using data from two publications
344	describing household SARS-CoV-2 transmission. A study of SARS-CoV-2
345	transmission in households inferred bottleneck sizes for 20 cases of infection ³² . We
346	took these sizes as being indicative of viral transmission events. Next, we used the
347	result from a meta-analysis of household transmission studies, of a secondary attack
348	rate for SARS-CoV-2 of 18.9% ³³ , to estimate that for each 20 cases of infection,
349	there were an additional 83 cases of exposure not leading to infection. We thus
350	compiled a dataset of 103 outcomes of exposure, 20 of which matched the
351	bottlenecks inferred by Lythgoe et al, and 83 of which involved zero viruses. Data
352	describing inferred bottlenecks for these 20 cases is shown in Figure S3.
353	

For a given set of parameters α and β , we represented the gamma distribution by a discrete set of 999 equally spaced quantiles $E_i(\alpha, \beta)$. We then calculated the mean likelihood of observing each bottleneck n_j in the dataset, summing these over the different bottleneck sizes.

$$\log L(\alpha,\beta|\{n_j\}) = \sum_{j=1}^{103} \frac{1}{999} \sum_{i=1}^{999} \log P\left(N_b = n_j|E_i(\alpha,\beta)\right)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

$$(7)$$

364 Combined model of viral transmission in the presence or absence of treatment with UDCA 365 366 367 Under the assumption of a linear relationship between ACE2 expression and viral infection, we derived a model of viral transmission in treated and untreated 368 individuals in a heterogeneous population. In our model, a person p receives a 369 370 stochastic exposure e to viruses characterised by a random draw from the Gamma 371 distribution $E(\alpha, \beta)$. 372 (8) $e \sim E(\alpha, \beta)$ 373

374

This exposure was scaled in a linear fashion by the individual-specific term I(r, t), which describes the relative ACE2 expression of the person. Here the parameter r was uniformly sampled from the interval (0,1); for example r=0.12 would imply that I(r, t)=x was equal to the 12th centile of the distribution G(a, b, t, x). In this manner, the effective exposure of a person p who had undergone t days of treatment with UDCA, was described as

381

$$E_p = \frac{I(r,t)}{I(r,0)}e$$
⁽⁹⁾

382

384 where the denominator represents the mean level of ACE2 expression for an

385 untreated individual. The number of viruses initiating infection in this person was

then given by the Poisson random variable

387

$$P(N_b = n|E_p) = \frac{E_p^n e^{-E_p}}{n!}$$
⁽¹⁰⁾

388

389

In this model, infection occurred if N_b was greater or equal to 1, and did not occur if

391 N_b was equal to zero. Basic statistics of infection were calculated across

392 distributions of ACE2 expression for treated and untreated individuals, integrating

393 over a representative range of levels of exposure.

394

395 Simulation of hospital transmission events

396

397 We used a published individual-based model of nosocomial transmission to simulate 398 SARS-CoV-2 in hospitals, including the importation of cases from the community, the occasional spread of infection between patients and health care workers (HCWs) in 399 hospitals, and the detection or non-detection of these cases³⁹. Within this modelling 400 401 framework simulations were conducted describing high, realistic, and low levels of importation of cases into hospitals. 'Realistic' levels were derived from now-casted 402 403 community levels of infection for the East of England, spanning a window of 600 days during the SARS-CoV-2 pandemic⁴⁰. High and low levels represented 2-fold 404 405 and 0.5 fold changes to these values. For each level of importation, twenty sets of parameters representing rates of transmission to and from healthcare workers and 406 407 patients were generated, consistent with evidence from a study of transmission in

408 hospitals⁴¹. Three statistical replicates were generated for each set of parameters,
409 making a total of 180 simulations.

410

For each simulation, transmission networks were identified, comprising sets of 411 patients and HCWs who infected each other in hospital, alongside the dates of these 412 transmission events. We modelled an intervention in which, upon the detection of a 413 414 case of SARS-CoV-2, all patients on the ward in which the case was detected were given a 10-day course of treatment with UDCA. Where new patients arrived on the 415 416 ward within 10 days of the commencement of the intervention, these patients were also started on a 10-day course of UDCA treatment. We then retrospectively altered 417 the identified transmission networks. Transmission events in these networks were 418 419 assigned a probability of occurrence equal to one. These probabilities were then 420 altered according to UDCA treatment, with a treated patient having a reduced probability of being infected. Alterations in probabilities were then evaluated in a 421 422 compound manner. For example, if in a simulation person A infected person B, who 423 infected person C, treating person B would reduce the probability of person C being infected, even if C was untreated. The expected reduction in the number of cases of 424 SARS-CoV-2 nosocomial infection was therefore calculated. 425

426

Our model of nosocomial transmission accounted for the variation in baseline
susceptibility to SARS-CoV-2 infection implied by our model of infection and
treatment. To achieve this we generated a distribution of the baseline ACE2
expression of an individual conditional upon their having been infected with SARSCoV-2. This distribution differs from the gamma distribution fitted to the untreated

ACE2 expression levels: The fact of having been infected increases the probability ofan individual having a high level of baseline ACE2 expression.

434

To calculate the conditional distribution of ACE2 we calculated quantiles of the distributions of baseline ACE2 expression G(a, b, 0, x), and of the exposure distribution $E(\alpha, \beta)(y)$, calculating the products of these values. We then identified probabilities of infection for each datapoint, normalising these to sum to one

440
$$P(x,y) = \frac{1 - e^{-G(a,b,0,x)E(\alpha,\beta)(y)}}{\sum_{x,y} 1 - e^{-G(a,b,0,x)E(\alpha,\beta)(y)}}$$

441

442 These values were then normalised to sum to one across all x and y, before 443 summing across exposures y to calculate a probability distribution from which values of ACE2 expression could be sampled. In evaluating nosocomial transmission, 444 individuals who were infected in the initial simulation were assigned baseline levels 445 446 of ACE2 expression from this discrete distribution before evaluating the individual-447 specific effect of UDCA upon their probability of having been infected. The discrete distribution and the inferred probability density function are shown in Supplementary 448 Figure S6. 449

450

451 Availability of code

452

453 Code used for processing simulation data is available at

454 https://github.com/cjri/HospitalSimulationAnalysis

456 Acknowledgements

- 457
- 458 This research is jointly funded by the UK Medical Research Council (MRC)
- 459 (MC_UU_00034/6) and the Foreign Commonwealth and Development Office
- 460 (FCDO) under the MRC/FCDO Concordat agreement.

462 **References**

- 464 1. Mizumoto, K. & Chowell, G. Estimating Risk for Death from Coronavirus Disease,
- 465 China, January–February 2020. *Emerg. Infect. Dis.* **26**, 1251–1256 (2020).
- 466 2. Poletti, P. *et al.* Age-specific SARS-CoV-2 infection fatality ratio and associated risk
- 467 factors, Italy, February to April 2020. *Eurosurveillance* **25**, (2020).
- 468 3. Andrews, N. et al. Duration of Protection against Mild and Severe Disease by Covid-
- 469 19 Vaccines. N. Engl. J. Med. **386**, 340–350 (2022).
- 470 4. Goldberg, Y. et al. Protection and Waning of Natural and Hybrid Immunity to SARS-
- 471 CoV-2. N. Engl. J. Med. **386**, 2201–2212 (2022).
- 5. Willett, B. J. et al. Omicron BA.2.86 cross-neutralising activity in community sera
- 473 from the UK. *The Lancet* **402**, 2075–2076 (2023).
- 474 6. Najjar-Debbiny, R. *et al.* Effectiveness of Paxlovid in Reducing Severe Coronavirus
- 475 Disease 2019 and Mortality in High-Risk Patients. *Clin. Infect. Dis.* **76**, e342–e349
- 476 (2023).
- 477 7. Gottlieb, R. L. *et al*. Early Remdesivir to Prevent Progression to Severe Covid-19 in
- 478 Outpatients. *N. Engl. J. Med.* **386**, 305–315 (2022).
- 479 8. Jayk Bernal, A. *et al.* Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized
 480 Patients. *N. Engl. J. Med.* 386, 509–520 (2022).
- 481 9. U.S. Food and Drug Administration. FDA Roundup: March 22, 2024.
- 482 https://www.fda.gov/news-events/press-announcements/fda-roundup-march-22-
- 483 2024 (2024).
- 484 10. Standing, J. F. *et al.* Randomized controlled trial of molnupiravir SARS-CoV-2 viral
- 485 and antibody response in at-risk adult outpatients. *Nat. Commun.* **15**, 1652 (2024).

- 486 11. Talic, S. *et al.* Effectiveness of public health measures in reducing the incidence of
- 487 covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and
- 488 meta-analysis. *BMJ* e068302 (2021) doi:10.1136/bmj-2021-068302.
- 489 12. Horita, N. & Fukumoto, T. Global case fatality rate from COVID-19 has decreased by
- 490 96.8% during 2.5 years of the pandemic. *J Med Virol* **95**, e28231 (2023).
- 491 13. Hamilton, W. L. *et al.* Applying prospective genomic surveillance to support
- 492 investigation of hospital-onset COVID-19. *Lancet Infect. Dis.* S1473309921002516
- 493 (2021) doi:10.1016/S1473-3099(21)00251-6.
- 494 14. Ferris, M. et al. Efficacy of FFP3 respirators for prevention of SARS-CoV-2 infection in
- 495 healthcare workers. *eLife* **10**, e71131 (2021).
- 496 15. Mehra, R., Patterson, B. J., Riley, P. A., Planche, T. D. & Breathnach, A. S. Impact of
- 497 removing the healthcare mask mandate on hospital-acquired COVID-19 rates. J.
- 498 Hosp. Infect. **145**, 59–64 (2024).
- 499 16. Butler, M. J. et al. Impact of supplementary air filtration on aerosols and particulate
- 500 matter in a UK hospital ward: a case study. J. Hosp. Infect. **135**, 81–89 (2023).
- 501 17. Brock, R. C. *et al.* Efficacy of Air Cleaning Units for preventing SARS-CoV-2 and other
- 502 hospital-acquired infections on medicine for older people wards: A quasi-
- 503 experimental controlled before-and- after study. J. Hosp. Infect.
- 504 S0195670124003256 (2024) doi:10.1016/j.jhin.2024.09.017.
- 18. Makhoul, M. *et al.* Modeling the population-level impact of treatment on COVID-19
- 506 disease and SARS-CoV-2 transmission. *Epidemics* **39**, 100567 (2022).
- 507 19. Gaziano, L. *et al*. Actionable druggable genome-wide Mendelian randomization
- identifies repurposing opportunities for COVID-19. *Nat. Med.* **27**, 668–676 (2021).

- 509 20. Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to
- 510 the ACE2 receptor. *Nature* **581**, 215–220 (2020).
- 511 21. Yaugel-Novoa, M., Bourlet, T., Longet, S., Botelho-Nevers, E. & Paul, S. Association
- of IFNAR1 and IFNAR2 with COVID-19 severity. *Lancet Microbe* **4**, e487 (2023).
- 513 22. Rodrigues, R. & Costa De Oliveira, S. The Impact of Angiotensin-Converting Enzyme
- 514 2 (ACE2) Expression Levels in Patients with Comorbidities on COVID-19 Severity: A
- 515 Comprehensive Review. *Microorganisms* **9**, 1692 (2021).
- 516 23. Brevini, T. et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing
- 517 ACE2. *Nature* **615**, 134–142 (2023).
- 518 24. John, B. V. et al. Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2
- 519 infection and reduced severity of COVID-19 in patients with cirrhosis. *J. Intern. Med.*520 **293**, 636–647 (2023).
- 521 25. Corpechot, C., Verdoux, M., Frank-Soltysiak, M., Duclos-Vallée, J. & Grimaldi, L.
- 522 Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-world
- 523 setting. J. Med. Virol. **96**, e29418 (2024).
- 524 26. Gao, H., Wang, J., Zheng, X., Cao, Y. & Jiang, E. Effect of Ursodeoxycholic Acid for
- 525 Sars-Cov-2 Prevention in Hematological Malignancies: An Observational Real-World
 526 Study. *Blood* 142, 7308–7308 (2023).
- 527 27. Li, Y., Zhu, N., Cui, X., Lin, Y. & Li, X. Protective effect of ursodeoxycholic acid on
- 528 COVID-19 in patients with chronic liver disease. *Front. Cell. Infect. Microbiol.* 13,
 529 1178590 (2023).
- 530 28. Ming, S. W. Y. M., Smith, M. & Zhou, Y. A Retrospective Study in Patients With Varying
- 531 Prescription Coverage With Ursodeoxycholic Acid and Association With Incidence

- of COVID-19 Diagnosis in Primary Care. *Microbiol. Infect. Dis. Am. Med. J.* (2023)
- 533 doi:10.33590/microbiolinfectdisamj/10304488.
- 534 29. Hu, L. *et al.* Effect of ursodeoxycholic acid on preventing SARS-CoV-2 infection in
- 535 patients with liver transplantation: a multicenter retrospective cohort study. *QJM*
- 536 hcad254 (2023) doi:https://doi.org/10.1093/qjmed/hcad254.
- 537 30. Gao, H. et al. Ursodeoxycholic acid does not reduce SARS-CoV-2 infection in newly
- allogeneic hematopoietic stem cell transplantation recipients: a prospective NICHE
- 539 cohort. *Front. Cell. Infect. Microbiol.* **14**, 1324019 (2024).
- 540 31. Sinclair, P., Zhao, L., Beggs, C. B. & Illingworth, C. J. R. The airborne transmission of
- 541 viruses causes tight transmission bottlenecks. *Nat. Commun.* **15**, 3540 (2024).
- 542 32. Lythgoe, K. A. et al. SARS-CoV-2 within-host diversity and transmission. Science
- 543 eabg0821 (2021) doi:10.1126/science.abg0821.
- 544 33. Madewell, Z. J., Yang, Y., Longini, I. M., Halloran, M. E. & Dean, N. E. Factors
- 545 Associated With Household Transmission of SARS-CoV-2: An Updated Systematic
- 546 Review and Meta-analysis. *JAMA Netw. Open* **4**, e2122240 (2021).
- 547 34. Poupon, R. E., Poupon, R., Balkau, B. & The UDCA-PBC study group. Ursodiol for the
- 548 long-term treatment of primary biliary cirrhosis. N. Engl. J. Med. 330, 1342–47
- 549 (1994).
- 550 35. Goutelle, S. *et al*. The Hill equation: a review of its capabilities in pharmacological
- 551 modelling. *Fundam*. *Clin*. *Pharmacol*. **22**, 633–648 (2008).
- 552 36. Schwarz, G. Estimating the dimension of a model. *Ann. Statist.* **6**, 461–464 (1978).
- 553 37. Raferty, A. Bayesian Model Selection in Social Research. Sociol. Methodol. 25, 111–
- 554 163.

- 555 38. Bergstrom, C. T., McElhany, P. & Real, L. A. Transmission bottlenecks as
- determinants of virulence in rapidly evolving pathogens. *Proc. Natl. Acad. Sci.* 96,
- 557 5095–5100 (1999).
- 558 39. Evans, S. et al. Impact of interventions to reduce nosocomial transmission of SARS-
- 559 CoV-2 in English NHS Trusts: a computational modelling study. *BMC Infect. Dis.* 24,
- 560 475 (2024).
- 40. Birell, P., Blake, J., van Leeuwen, E., Gent, N., & De Angelis, Daniela. Real-time
- 562 nowcasting and forecasting of COVID-19 dynamics in England: the first wave. *Philos*.
- 563 Trans. R. Soc. B Biol. Sci. **376**, 20200279. (2021).
- 564 41. Lindsey, B. B. et al. Characterising within-hospitalSARS-CoV-2 transmission events
- 565 using epidemiological and viral genomic data across two pandemic waves. *Nat*.
- 566 *Commun.* **13**, 671 (2022).
- 567

569 Figures

570



572

573 Figure 1: Basic model details. A. Distribution of SARS-CoV-2 exposure used in 574 our model. An exposure of 1 means that an individual is infected by a Poisson random variable with parameter 1. If this random variable is equal to or greater than 575 1, the individual is infected, rather than not infected. **B.** Derived distribution of ACE2 576 577 expression levels in treated and untreated individuals. C. Effective exposure distributions for treated and untreated individuals. People who are taking UDCA are 578 less likely to be infected by larger numbers of viruses. D. Adjusted odds ratios of 579 infection calculated across a population of individuals with a distribution of ACE2 580 581 levels.



```
584
```

585 Figure 2: Application of UDCA treatment to a transmission network A. Case of nosocomial transmission within a hospital simulation. Horizonal lines show times 586 when individuals were in the hospital, coloured blue for patients or red for HCWs. 587 588 Black dots indicate dates on which individuals were infected, while squares indicate dates on which cases of infection were detected, where detection occurred. B. 589 590 Representation of one realisation of the impact of UDCA treatment upon the transmission network. The ward upon which the outbreak began was an intervention 591 ward at the time of patient 953 being introduced onto the ward. UDCA treatment 592

- reduced the probabilities of patients being infected with SARS-CoV-2, and by
- implication reducing the probabilities of their further transmitting the virus. The
- reductions in individual probabilities caused by UDCA are stochastic, representing
- random samplings of the baseline ACE2 levels of expression of individuals. **C.**
- 597 Numbers of secondary cases of SARS-CoV-2 infection in patients and HCWs in the
- 598 network in the absence of an intervention. **D.** Numbers of secondary cases given
- 599 treatment with UDCA.



602

Figure 3. Reduction in transmission caused by the simulated use of UDCA. A. 603

604 Reductions in nosocomial transmissions to patients, measured across five stochastic 605 replicates of each of 60 hospital simulations. **B.** Reductions in nosocomial transmission events to healthcare workers, measured across five stochastic 606 607 replicates of each of 60 hospital simulations. C. Variation in the reduction in nosocomial transmissions to patients, varying the length of the intervention, given 608 the detection of a case upon a ward. **D.** Total length of interventions in a hospital 609 according to the length of an individual intervention, measured in ward-days, across 610 611 the 624 days of the simulation.







- calculated across 60 simulations with a high importation rate. The gray shaded 626
- region shows the range across simulations. 627

628

630

631 Supplementary Figures

632



634 Figure S1. Data describing changes in ACE2 expression following the use of

635 UDCA. qPCR measurements of the levels of ACE2 in nasal epithelial cells collected

636 with nasopharyngeal swabs from six individuals who received 15 mg per kg per day

of UDCA for five days, previously described by Brevini et al²³. Shading indicates

638 windows of time into which samples were divided for model fitting. A gamma

639 distribution was fitted to the data within each window.



642



651





Figure S3: Data describing SARS-CoV-2 transmission bottlenecks, from an 655 earlier publication³². Data describe the number of SARS-CoV-2 viruses initiating 656 657 infection in 20 cases of household transmission. In our study these data were augmented with cases describing non-infection, that is with transmission bottleneck 658 zero, reflecting a published secondary attack rate for SARS-CoV-2 in a domestic 659 660 context³³. Our basic exposure model, described in Figure 1A, was then fitted to the augmented data. 661





663



- importation rates. A cluster size of 2 indicates one person infecting another, with 665
- no further transmission. 666

668



670

Figure S5: Expected distributions of SARS-CoV-2 transmission bottlenecks.

672Inferred values are shown for among individuals at the 10th and 90th centiles of ACE2673expression, in untreated individuals, and in individuals treated for more than three674days with UDCA. In both cases UDCA reduces expected bottleneck sizes, but with a675more dramatic reduction in the probability of transmission (i.e. bottleneck size \geq 1)676among individuals with low ACE2 expression.677

678





Figure S6: Distribution of baseline ACE2 expression conditional upon an 682

- individual having been infected. A. Probabilities of discrete values of baseline 683
- ACE2 expression. **B.** Probability density function implied by the discrete distribution. 684